Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: A pilot study

Cornea

Volumn 31, Issue 2, 2012, Pages 155-161

  Lekhanont, Kaevalin ^a   Patarakittam, Thanikan ^a   Thongphiew, Prakairut ^a   Suwan Apichon, Olan ^b   Hanutsaha, Prut ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

bevacizumab; impending recurrent pterygium; subconjunctival injection

Indexed keywords

BEVACIZUMAB; FLUOROMETHOLONE;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; PTERYGIUM; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, OPHTHALMIC; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONJUNCTIVA; FEMALE; FLUOROMETHOLONE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRALESIONAL; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PTERYGIUM; RECURRENCE; SINGLE-BLIND METHOD; TONOMETRY, OCULAR; VISUAL ACUITY;

EID: 84855825280     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182151e0e     Document Type: Article

References (22)

1. Todani A, Melki SA. Pterygium: current concepts in pathogenesis and treatment. Int Ophthalmol Clin. 2009;49:21-30.
2. Chui J, Di Girolamo N, Wakefield D, et al. The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf. 2008;6:24-43. (Pubitemid 351902631)
3. Tan DT, Chee SP, Dear KB, et al. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115: 1235-1240.
4. Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision. Ophthalmology. 1997;104:974-985. (Pubitemid 27255410)
5. Prabhasawat P, Tesavibul N, Leelapatranura K, et al. Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium. Ophthalmology. 2006;113:1102-1109. (Pubitemid 43947236)
6. Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18:308-313. (Pubitemid 46955297)
7. Paris Fdos S, de Farias CC, Melo GB, et al. Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence. Cornea. 2008; 27:406-410. (Pubitemid 351591476)
8. Mauro J, Foster CS. Pterygia: pathogenesis and the role of sub-conjunctival bevacizumab in treatment. Semin Ophthalmol. 2009;24: 130-134.
9. Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses. 2007;69: 925-927. (Pubitemid 47248101)
10. Murube J. Pterygium: evolution of medical and surgical treatments. Ocul Surf. 2008;6:155-161.
11. Fallah MR, Khosravi K, Hashemian MN, et al. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res. 2010;35:17-22.
12. Razeghinejad MR, Hosseini H, Ahmadi F, et al. Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res. 2010;43:134-138.
13. Mansour AM. Treatment of inflamed pterygia or residual pterygial bed. Br J Ophthalmol. 2009;93:864-865.
14. Leippi S, Grehn F, Geerling G. Antiangiogenic therapy for pterygium recurrence. Ophthalmologe. 2009;106:413-419.
15. Teng CC, Patel NN, Jacobson L. Effect of subconjunctival bevacizumab on primary pterygium. Cornea. 2009;28:468-470.
16. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea. 2009;28:103-104.
17. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
18. You IC, Kang IS, Lee SH, et al. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009;87:653-658.
19. Pikkel J, Porges Y, Ophir A. Halting pterygium recurrence by postoperative 5-fluorouracil. Cornea. 2001;20:168-171. (Pubitemid 32174086)
20. Dastjerdi MH, Saban DR, Okanobo A, et al. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci. 2010;51:2411-2417.
21. Beer PM, Wong SJ, Hammad AM, et al. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina. 2006;26:871-876. (Pubitemid 44547438)
22. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993. (Pubitemid 47615364)